Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis

Trial Profile

Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SUN 0597 (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Sun Pharma Advanced Research Company
  • Most Recent Events

    • 01 Sep 2016 Primary endpoint (Change in Total Nasal Symptom Score From Baseline to Day 14) has been met, according to the results published in the Annals of Allergy, Asthma and Immunology .
    • 01 Sep 2016 Results published in the Annals of Allergy, Asthma and Immunology (2016).
    • 08 Apr 2016 Treatment arms changed from 5 to 4 with removal of active comparator as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top